SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradio...

Descripción completa

Detalles Bibliográficos
Autores principales: Vera, R., Dotor, E., Feliu, J., González, E., Laquente, B., Macarulla, T., Martínez, E., Maurel, J., Salgado, M., Manzano, J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Clinical Guides in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138250/
https://www.ncbi.nlm.nih.gov/pubmed/27896637
http://dx.doi.org/10.1007/s12094-016-1586-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138250/
https://www.ncbi.nlm.nih.gov/pubmed/27896637
http://dx.doi.org/10.1007/s12094-016-1586-x

Ejemplares similares